PET/CT Scans for Head Neoplasms

Phase-Based Progress Estimates
Head Neoplasms+1 More
PET/CT Scans - DiagnosticTest
All Sexes
What conditions do you have?

Study Summary

This trial is testing if PARPi-FL is safe for humans and if it can be used to take pictures of head and neck cancer like other imaging tests.

Eligible Conditions
  • Head Neoplasms
  • Head and Neck Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 2 years

2 years
severity of adverse events

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

[18 F]-PARPi and PET/CT Scans
1 of 1
Experimental Treatment

12 Total Participants · 1 Treatment Group

Primary Treatment: PET/CT Scans · No Placebo Group · Phase 1

[18 F]-PARPi and PET/CT ScansExperimental Group · 2 Interventions: PET/CT Scans, [18F]- PARPi · Intervention Types: DiagnosticTest, Drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 2 years

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor
1,821 Previous Clinical Trials
584,335 Total Patients Enrolled
Heiko Schöder, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
5 Previous Clinical Trials
1,263 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 7 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 1st, 2021

Last Reviewed: October 1st, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.